Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Illumina Laboratory Services, |
RCV000330893 | SCV000359511 | uncertain significance | Stargardt Disease, Recessive | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000387710 | SCV000359512 | uncertain significance | Cone-Rod Dystrophy, Recessive | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000295678 | SCV000359513 | uncertain significance | Retinitis Pigmentosa, Recessive | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000343633 | SCV000359514 | uncertain significance | Macular degeneration | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000523526 | SCV000617270 | uncertain significance | not provided | 2017-08-07 | criteria provided, single submitter | clinical testing | The Y440C variant in the ABCA4 gene has been previously reported in the heterozygous state in an individual with cone rod dystrophy (Bauwens et al., 2015). While not observed in the homozygous state, the Y440C variant is observed in 20/16512 (0.12%) alleles from individuals of South Asian background in the ExAC dataset (Lek et al., 2016). The Y440C variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at a position that is not conserved, and in silico analysis is inconsistent in its predictions as to whether or not the variant is damaging to the protein structure/function. We interpret Y440C as a variant of uncertain significance. |
Illumina Laboratory Services, |
RCV001102042 | SCV001258690 | uncertain significance | ABCA4-related disorder | 2018-01-13 | criteria provided, single submitter | clinical testing | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. |
Labcorp Genetics |
RCV000523526 | SCV002205956 | uncertain significance | not provided | 2022-07-31 | criteria provided, single submitter | clinical testing | This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 440 of the ABCA4 protein (p.Tyr440Cys). This variant is present in population databases (rs770439859, gnomAD 0.1%). This missense change has been observed in individual(s) with cone-rod dystrophy (PMID: 25346251). ClinVar contains an entry for this variant (Variation ID: 298262). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C15"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Institute of Human Genetics, |
RCV004816525 | SCV005072187 | likely pathogenic | Retinal dystrophy | 2014-01-01 | criteria provided, single submitter | clinical testing |